Radioiodide (131I) therapy for the treatment of canine thyroid carcinoma

被引:48
|
作者
Worth, AJ
Zuber, RM
Hocking, M
机构
[1] Massey Univ, Vet Teaching Hosp, Ctr Compan Anim Hlth, Palmerston North, New Zealand
[2] Gladesville Vet Hosp, Gladesville, NSW 2111, Australia
关键词
D O I
10.1111/j.1751-0813.2005.tb11650.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Objective To assess the efficacy of radioactive iodine treatment (I-131) for canine thyroid carcinoma, as both the sole therapeutic modality and as an adjunct to surgery. Design Retrospective analysis of case records from the Gladesville Veterinary Hospital Nuclear Medicine Service, Sydney, between August 1988 and December 2001. Case Details The records of 65 dogs with thyroid carcinoma were analysed according to therapy and outcome. Forty-three dogs received radioiodide therapy, either as the sole therapeutic modality (32) or as an adjunct to surgery (11). Radioisotope therapy consisted of one to three doses of I-131 with a dose range of 555 to 1850 MBq. For analysis, dogs were divided into groups according to therapy: no treatment, surgery alone, surgery with radioiodide therapy or radioiodide therapy alone. Mode of therapy, dosage of I-131, clinical staging and age were all independently analysed according to survival to compare efficacy or predictive value respectively. Results When radioiodide therapy was used as an adjunct to surgery, median survival was 34 months. Censored median survival time for dogs that received radioiodide alone was 30 months. Dogs that did not receive treatment had a median survival of only 3 months. Log rank statistical analysis indicated that mode of therapy was significantly correlated with survival but that clinical stage of disease was not. Conclusion The authors conclude that I-131 therapy is effective at extending survival time, both as a sole therapeutic modality and as an adjunct to surgery, in dogs with invasive canine thyroid carcinoma. Incomplete surgical resection may not prolong survival in dogs also receiving I-131 therapy, however surgical resection with curative intent should be recommended as the first line of therapy for mobile thyroid carcinomas. Radioisotope therapy can be recommended for cases where surgery alone is considered unlikely to be curative because of metastatic disease or local invasion, or for cases where surgery has been attempted but complete surgical removal has not been achieved.
引用
收藏
页码:208 / 214
页数:7
相关论文
共 50 条
  • [31] 131I thyroid uptake in patients treated with 131I-Lipiodol for hepatocellular carcinoma
    Toubeau, M
    Touzery, C
    Berriolo-Riedinger, A
    Cochet, A
    Brunotte, F
    Bedenne, L
    Cercueil, JP
    Krause, D
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (05) : 669 - 670
  • [32] 131I thyroid uptake in patients treated with 131I-Lipiodol for hepatocellular carcinoma
    Michel Toubeau
    Claude Touzery
    Alina Berriolo-Riedinger
    Alexandre Cochet
    François Brunotte
    Laurent Bedenne
    Jean-Pierre Cercueil
    Denis Krause
    European Journal of Nuclear Medicine, 2001, 28 : 669 - 670
  • [33] 131I lipiodol therapy for unresectable hepatocellular carcinoma
    Rindani, RB
    Hugh, TJ
    Roche, J
    Roach, PJ
    Smith, RC
    ANZ JOURNAL OF SURGERY, 2002, 72 (03) : 210 - 214
  • [34] Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
    Salvatori, M
    Perotti, G
    Rufini, V
    Maussier, ML
    Dottorini, M
    CLINICAL ENDOCRINOLOGY, 2004, 61 (06) : 704 - 710
  • [35] 131I exhalation by patients undergoing therapy of thyroid diseases
    Gruendel, M.
    Kopka, B.
    Schulz, R.
    RADIATION PROTECTION DOSIMETRY, 2008, 129 (04) : 435 - 438
  • [36] Gonadal damage from 131I therapy for thyroid cancer
    Mazzaferri, EL
    CLINICAL ENDOCRINOLOGY, 2002, 57 (03) : 313 - 314
  • [37] Effects of recombinant human thyroid stimulating hormone on 131I therapy for the treatment of differentiated thyroid cancer
    Guo, Yiling
    Zhang, Yingnan
    Chen, Zuowei
    Xin, Zhenfu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 9 (05) : 1847 - 1850
  • [38] The influence of 131I therapy on thyroid volume in Graves' hyperthyroidism
    Pirnat, E
    Fidler, V
    Gaberscek, S
    Zaletel, K
    Hojker, S
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S465 - S465
  • [39] Dosimetric methodology for 131I therapy for benign thyroid diseases
    Piron, B.
    Broggio, D.
    Bardies, M.
    Barrau, C.
    Kotzki, P. O.
    Boudousq, V
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2020, 44 (04): : 261 - 266
  • [40] Prescribed Activity of 131I Therapy in Differentiated Thyroid Cancer
    Van Nostrand, Douglas
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (05) : 697 - 699